Biontech: CureVac Acquisition Sharpens mRNA Strategy!
Reading Time: 3 minutes
Biontech has completed the acquisition of the Tübingen biotech company CureVac, marking a significant strategic step to strengthen its technological foundation. After the end of the additional acceptance period, approximately 86.75% of CureVac's shares were tendered to the Mainz-based company. The mandatory acquisition of the remaining shares is planned for January 2026, after which a delisting of CureVac from the stock market is intended. With the completion of the transaction, Biontech is strategically enhancing its position in mRNA research...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
